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Background: Activities of daily living (ADL) are an essential part of the diagnostic criteria for Alzheimer’s disease
(AD). A decline in ADL affects independent living and has a strong negative impact on caregiver burden. Functional
response to cholinesterase inhibitor (ChEI) treatment and factors that might influence this response in naturalistic
AD patients need investigating. The aim of this study was to identify the socio-demographic and clinical factors
that affect the functional response after 6 months of ChEI therapy.
Methods: This prospective, non-randomised, multicentre study in a routine clinical setting included 784 AD
patients treated with donepezil, rivastigmine or galantamine. At baseline and after 6 months of treatment, patients
were assessed using several rating scales, including the Instrumental Activities of Daily Living (IADL) scale, Physical
Self-Maintenance Scale (PSMS) and Mini-Mental State Examination (MMSE). Demographic and clinical characteristics
were investigated at baseline. The functional response and the relationships of potential predictors were analysed
using general linear models.
Results: After 6 months of ChEI treatment, 49% and 74% of patients showed improvement/no change in IADL and
in PSMS score, respectively. The improved/unchanged patients exhibited better cognitive status at baseline;
regarding improved/unchanged PSMS, patients were younger and used fewer anti-depressants. A more positive
functional response to ChEI was observed in younger individuals or among those having the interaction effect of
better preserved cognition and lower ADL ability. Patients with fewer concomitant medications or those using
NSAIDs/acetylsalicylic acid showed a better PSMS response.
Conclusions: Critical characteristics that may influence the functional response to ChEI in AD were identified. Some
predictors differed from those previously shown to affect cognitive response, e.g., lower cognitive ability and older
age predicted better cognitive but worse functional response.
Keywords: Alzheimer’s disease, Activities of daily living, Cholinesterase inhibitors, Treatment effect, Predictors,
Statistical modelsBackground
Functional ability is important in Alzheimer’s disease
(AD), as it reflects the individual’s capacity to carry out
daily activities (ADL) in real-life situations; thus, it may
be indicative of how the patient is able to manage in so-
ciety. Deterioration in daily functions accompanies the
more commonly investigated cognitive symptoms in AD* Correspondence: carina.wattmo@skane.se
1Clinical Memory Research Unit, Department of Clinical Sciences, Malmö,
Lund University, Malmö, Sweden
2Memory Clinic, Skåne University Hospital, SE-205 02 Malmö, Sweden
© 2012 Wattmo et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orof impairment in memory, orientation and executive abi-
lity [1]. In addition to causing distress to the patient, a
decline in ADL has a strong negative impact on the
caregivers’ burden [2] and contributes to the rising soci-
etal cost of dementia [3]. A faster decline in function, ra-
ther than in cognition, has been described as a factor
that could precipitate nursing-home placement [4,5]. A
treatment that delays the deterioration of the individual’s
functional abilities could possibly reduce the growing pres-
sure on the family members and the usage of community-
based care [3].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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AD is cholinesterase inhibitor (ChEI) treatment. ChEIs
prevent the breaking down of acetylcholine by the acetyl-
cholinesterase enzyme, resulting in increased levels in the
synaptic cleft available for receptor absorption. This en-
hances cholinergic transmission and improves the com-
munication between neurons [6]. Randomized AD trials
have demonstrated that ChEIs are effective in slowing
functional decline compared with placebo-treated controls
[7-9], and “real world” studies have reported positive long-
term effects of ChEI on ADL [10,11]. The expected effect
of ChEI on function may slow or delay the deterioration
rather than promote the regaining of lost abilities [12].
The clinical value of these drugs is still controversial
among physicians. One study reported that the prevalence
of ChEI treatment was lower among older than it was
among younger AD patients [13].
Factors that might influence the short-term func-
tional response to ChEI therapy in AD patients in
naturalistic studies have not been investigated previ-
ously. In a recent paper, our group analysed the socio-
demographic and clinical factors that might affect the
long-term functional outcome in AD. A slower decline
in ability to perform ADL after 3 years of ChEI the-
rapy was associated with higher cognitive status at
baseline, younger age, and the interaction effect of
lower education and a longer time in the study. More-
over, a higher dose of ChEI, regardless of the drug
used, or living with a family member predicted a bet-
ter longitudinal outcome in IADL [10]. Some shorter
naturalistic studies have observed different results in
functional outcome between the three ChEI drugs
[14,15].
The short-term cognitive response to ChEI therapy
has been reported as heterogeneous among individuals
with AD. Some studies have focused on different cog-
nitive responses to ChEIs based on socio-demographic
and clinical characteristics. A better cognitive response
to treatment was observed in patients with a fast pre-
treatment progression rate [16,17], in patients who were
more cognitively impaired [9,18,19], in males [19,20],
and in patients taking larger doses of ChEIs [19,21];
however, these results were not conclusive [22,23]. Incon-
sistent results have been described regarding age [14,24]
and apolipoprotein E (APOE) genotype [9,25].
The identification of subgroups of functional responses
to ChEI may provide valuable prognostic information
to clinicians and social service providers and treat-
ment recommendations for clinical practice, as well as
increased knowledge regarding counselling patients and
their families about the treatment effect.
The aim of this study was to identify the socio-
demographic and clinical factors that have an impact on
functional response after 6 months of ChEI therapy.Methods
Study and subjects
The Swedish Alzheimer Treatment Study (SATS) was
started to investigate the long-term effectiveness of ChEI
treatment (donepezil, rivastigmine and galantamine) in
naturalistic AD patients in a routine clinical setting. SATS
is a 3-year, open-label, observational, non-randomised,
multicentre study that was described in detail in a pre-
vious publication [26]. Most patients were in the mild-to-
moderate stages of the disease and were prospectively
recruited from 14 memory clinics in Sweden.
Seven hundred and eighty-four individuals with base-
line Mini-Mental State Examination (MMSE) [27] scores
ranging from 10 to 26 and a fulfilled 6-month post-
baseline assessment were included up until the end of
December 2005, thereby having the opportunity to
complete the full 3-year SATS programme.
Outpatients aged 40 years and older who received the
clinical diagnosis of dementia as defined by the Diag-
nostic and Statistical Manual of Mental Disorders, 4th
edition (DSM-IV) [28] and possible or probable AD ac-
cording to the criteria of the National Institute of
Neurological and Communicative Disorders and Stroke
and the Alzheimer’s Disease and Related Disorders As-
sociation (NINCDS–ADRDA) [29] were considered for
inclusion. In addition, the selected patients had to be li-
ving at home at the time of diagnosis, had to have a re-
sponsible caregiver and had to be assessable using the
MMSE at the start of ChEI treatment (baseline). Patients
who did not fulfil the diagnostic criteria for AD or those
already receiving active treatment with ChEI (i.e., the
patients were naïve at baseline), or individuals with con-
traindications to ChEI were excluded from the study. If
ChEI treatment was stopped or the patient switched to
another ChEI agent or other dementia treatments such
as memantine or study drugs were added, the patient
was excluded from the study at that point. Medications
other than anti-dementia drugs were allowed and docu-
mented during the study.
All patients and/or caregivers gave their informed con-
sent to participate in the study, which was conducted
according to the provisions of the Helsinki Declaration
and was approved by the Ethics Committee of Lund
University, Sweden.
The SATS patients were assessed in a structured follow-
up program, which evaluated cognition, global perfor-
mance, ADL and community-based service utilization at
the start of ChEI treatment and semi-annually for a period
of 3 years. The assessments at baseline were performed
before and close to the start of ChEI therapy. The ChEI
dose was recorded after 2 months of treatment, and every
6 months after the baseline assessment. Trained dementia
nurses obtained the ADL evaluation from an inter-
view with the caregiver. After inclusion and baseline
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The Instrumental Activities of Daily Living scale (IADL)
[30] consists of eight items: ability to use the telephone,
shopping, food preparation, housekeeping, ability to do
laundry, mode of transportation, responsibility for own
medications and ability to handle finances. Each item
was scored from 1 (no impairment) to 3–5 (severe im-
pairment), giving a total range of 8–31 points. Some of
the instrumental activities could be gender dependent
among the elderly; therefore, a mathematical correction
of the sum of the IADL scores was performed, to avoid
these activities affecting the results. The transformation
used the data from the rated items to estimate a total
score within the range of the total IADL scale [5].
PSMS
The Physical Self-Maintenance Scale (PSMS) [30] con-
sists of six items: toilet, feeding, dressing, grooming,
physical ambulation and bathing. Each item was scored
from 1 (no impairment) to 5 (severe impairment), allo-
wing a total range of 6–30 points.
Cognitive tests
Cognitive ability was assessed using the MMSE, with a
range from 0 to 30, in which a lower score indicates
more impaired cognition, and using the Alzheimer’s Di-
sease Assessment Scale-cognitive subscale (ADAS-cog)
(0–70 points) [31], in which a lower score indicates bet-
ter cognition.
Definition of functional response
The improved/unchanged groups were defined as ≥ 0
point change in IADL or PSMS score, respectively, bet-
ween the start of ChEI therapy and the 6-month assess-
ment. Consequently, the deteriorated group had lower
ADL ability of at least 1 point after 6 months of treat-
ment. To facilitate comparisons between the MMSE,
ADAS-cog, IADL and PSMS assessment scales, changes
in the scores reflected as positive values were interpreted
as indicating improvement and negative values as indi-
cating worsening.
Statistical analyses
The Statistical Package for Social Sciences (SPSS) soft-
ware (version 19.0; SPSS Inc., Chicago, IL, USA) was
used to perform the statistical analyses. The level of
significance was defined as p < 0.05 if not otherwisespecified, and all tests were two-tailed. Parametric tests
were used because of the large sample and the approxi-
mately normally distributed continuous potential predic-
tors. Independent samples t tests were used to compare
the differences between the means for the responder
groups, and χ2 tests were computed for analyses of cat-
egorical variables. Pearson’s correlation coefficient was
calculated to investigate any linear associations between
continuous variables.
General linear models
In this study, we used general linear models to achieve a
multivariate resolution in the analysis of the association
between potential predictive independent characteristics,
including a comparison of the three ChEI agents, on the
functional response to treatment in a routine clinical set-
ting. The dependent normally distributed variables were
the change in IADL or PSMS score after 6 months,
respectively. Several socio-demographic and clinical
background variables were included in the models as
independent variables. The selection of these variables
was based on evidence-based knowledge and well-
known risk factors of AD. The selected background
variables were: age at first assessment, clinician’s estimate of
age at onset or duration of AD, gender, years of education,
APOE ε4 carrier status, solitary living, functional status at
baseline measured by IADL or PSMS, cognitive severity at
baseline measured by MMSE or ADAS-cog, medication
use (antihypertensive/cardiac therapy, anti-diabetic drugs,
lipid-lowering agents, estrogens, non-steroidal anti-
inflammatory drugs (NSAIDs)/acetylsalicylic acid,
anti-depressants, anti-psychotics or anxiolytics/sedatives/
hypnotics), type of ChEI agent and drug dose.
Because of the strong linear correlation between MMSE
and ADAS-cog scores, these variables were entered sepa-
rately in the models. Similarly, the potential predictors of
age at onset and duration of AD were also entered separ-
ately. The ChEI agents were coded as a set of dummy vari-
ables. The ChEI dose could vary during the treatment
period for an individual patient and between patients.
Therefore, the mean dose used during the first 6 months of
therapy was calculated for each patient. Furthermore, to ob-
tain a similar metric of percent maximum dosage for the
three ChEI agents, the mean dose was divided by the max-
imum recommended dose for each drug agent, i.e., 10 mg
donepezil, 12 mg rivastigmine and 24 mg galantamine. The
rivastigmine dose refers to oral therapy. Finally, the possible
interaction effects of ADL (IADL or PSMS) ability with gen-
der, age or cognitive status were included in the models.
The term “type of ChEI with dose” was also included. Non-
significant variables (p > 0.05) were removed in a backward
stepwise elimination manner. The hierarchical principle was
observed in these analyses; terms that appeared in interac-
tions were not considered for elimination.
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Responder groups
The 784 patients were divided into two groups accord-
ing to the difference in IADL and PSMS score after 6
months of ChEI treatment: improved/unchanged (IADL,
n = 383 (49%); PSMS, n = 578 (74%)) and deteriorated
(IADL, n = 401 (51%); PSMS, n = 206 (26%)).
The socio-demographic and clinical characteristics of
the two groups are displayed in Table 1. The
improved/unchanged IADL group showed a signifi-
cantly better cognitive status at baseline measured
by ADAS-cog score (t(768) = 2.18; p = 0.030) (but
not using the MMSE) and a lower instrumental ADL
ability (t(782) = −2.82; p = 0.005). The improved/un-
changed PSMS group was younger at the onset of AD
(t(778) = 2.28; p = 0.023) and at the start of ChEI treatment
(t(782) = 2.73; p = 0.007). This group also exhibited signifi-
cantly better preservation compared with the deteriorated
PSMS group regarding the mean MMSE (t(782) = −5.94;
p < 0.001), ADAS-cog (t(768) = 6.53; p < 0.001) and IADL
(t(782) = 7.15; p < 0.001) scores at the start of treatment. In
addition, 23% of the patients in the improved/unchanged
PSMS group used anti-depressants at baseline comparedTable 1 Demographic and clinical characteristics
IADL
Improved/ unchanged Deteriora
Variable n = 383 (49%) n = 401 (5
Female gender 232 (61%) 264 (66
APOE ε4 carrier, (n=771) 257 (68%) 268 (68
Solitary living at baseline 116 (30%) 141 (35
Antihypertensives/Cardiac therapy 156 (41%) 158 (39
Anti-diabetics 19 (5%) 14 (3%
Lipid-lowering agents 46 (12%) 39 (10%
Estrogens 21 (5%) 35 (9%
NSAIDs/Acetylsalicylic acid 116 (30%) 117 (29
Anti-depressants 91 (24%) 107 (27
Anti-psychotics 11 (3%) 20 (5%
Anxiolytics/Sedatives/Hypnotics 54 (14%) 51 (13%
Variable Mean ± standard deviation
Estimated age at onset, years 71.8 ± 7.2 71.9 ± 7
Age at first assessment, years 74.8 ± 7.1 75.0 ± 7
Education, years 9.3 ± 2.4 9.4 ± 2
MMSE score at baseline 21.6 ± 3.8 21.1 ± 3
ADAS-cog score (0–70) at baseline 20.0 ± 8.9 21.4 ± 8
IADL score at baseline 16.4 ± 5.9 15.3 ± 4
PSMS score at baseline 7.5 ± 2.2 7.5 ± 2
Number of medications at baseline 3.0 ± 2.5 2.7 ± 2
ADAS-cog Alzheimer’s Disease Assessment Scale-cognitive subscale, APOE apolipopr
State Examination, NSAID non-steroidal anti-inflammatory drugs, PSMS Physical Selfwith 33% in the deteriorated PSMS group (χ2(1) = 7.45;
p = 0.007).
Older age at the start of ChEI therapy demonstrated
weak linear associations with lower ADL (n = 784;
IADL: r = 0.292, p < 0.001; PSMS: r = 0.249, p < 0.001)
and cognitive abilities (ADAS-cog: n = 770, r = 0.098,
p = 0.005), but not with measured MMSE score. A
higher number of medications at baseline correlated
weakly with increased functional impairment (n = 782;
IADL: r = 0.170, p < 0.001; PSMS: r = 0.171, p < 0.001)
and higher age (n = 782, r = 0.245, p < 0.001), but not
with cognitive ability.
ChEI treatment
The number of individuals (%) treated with donepezil,
rivastigmine and galantamine was 436 (56%), 175 (22%)
and 173 (22%), respectively. During the first 6 months of
treatment, the mean ± standard deviation (SD) doses of
donepezil, rivastigmine and galantamine were 6.2 ± 1.6,
4.9 ± 1.3 and 12.4 ± 3.1 mg, respectively. No difference
in dose was detected between the improved/unchanged
and deteriorated groups.PSMS
ted P value Improved/ unchanged Deteriorated P value
1%) n = 578 (74%) n = 206 (26%)
%) 0.138 360 (62%) 136 (66%) 0.356
%) 1.000 387 (68%) 138 (68%) 1.000
%) 0.149 184 (32%) 73 (35%) 0.343
%) 0.716 237 (41%) 77 (38%) 0.407
) 0.374 29 (5%) 4 (2%) 0.068
) 0.358 65 (11%) 20 (10%) 0.603
) 0.095 37 (6%) 19 (9%) 0.206
%) 0.755 173 (30%) 60 (29%) 0.929
%) 0.366 131 (23%) 67 (33%) 0.007
) 0.145 20 (3%) 11 (5%) 0.296
) 0.601 70 (12%) 35 (17%) 0.094
P value Mean ± standard deviation P value
.7 0.969 71.5 ± 7.7 72.9 ± 6.8 0.023
.1 0.678 74.6 ± 7.4 76.0 ± 6.3 0.007
.5 0.388 9.4 ± 2.5 9.3 ± 2.5 0.755
.8 0.116 21.8 ± 3.5 20.0 ± 4.1 <0.001
.9 0.030 19.5 ± 8.5 24.1 ± 9.1 <0.001
.8 0.005 15.1 ± 5.3 18.1 ± 5.1 <0.001
.1 0.969 7.4 ± 2.1 7.7 ± 2.3 0.113
.3 0.216 2.8 ± 2.4 3.1 ± 2.4 0.101
otein E, IADL Instrumental Activities of Daily Living scale, MMSE Mini-Mental
-Maintenance Scale.
Table 2 Factors affecting the 6-month functional response to ChEI treatment (final general linear models)
Dependent variable, change from baseline IADL PSMS
Percentage of variance accounted for R2 = 0.310, p < 0.001 R2 = 0.335, p < 0.001
Significant predictors β 95% CI (β) p value β 95% CI (β) p value
Intercept −10.922 −15.585, –6.259 < 0.001 0.419 −2.156, 2.995 0.749
Age at first assessment, years −0.041 −0.070, –0.011 0.007 −0.018 −0.036, –0.001 0.036
ADL score at baselinea 0.521 0.300, 0.741 < 0.001 −0.175 −0.441, 0.090 0.196
MMSE score at baseline 0.453 0.267, 0.640 < 0.001 −0.021 −0.128, 0.086 0.697
Number of medications at baseline ns −0.079 −0.134, –0.024 0.005
NSAIDs/Acetylsalicylic acid (no = 0, yes = 1) ns 0.419 0.133, 0.705 0.004
Interaction terms:
ADL baseline scorea × MMSE baseline score −0.016 −0.026, –0.006 0.002 0.018 0.005, 0.032 0.008
Gender, APOE ε4 carrier status, solitary living, age at onset (or duration of AD), years of education and the variables comparing the ChEI agents and dose
were not significant.
β values are expressed per 1 unit increase for continuous variables and for the condition present in dichotomous variables
aADL = IADL or PSMS, respectively.
ChEI cholinesterase inhibitor, CI confidence interval, IADL Instrumental Activities of Daily Living scale, MMSE Mini-Mental State Examination, NSAID non-steroidal
anti-inflammatory drugs, ns not significant, PSMS Physical Self-Maintenance Scale.
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General linear models using change in IADL or PSMS
scores after the first 6 months of treatment as continuous
variables were built to identify the socio-demographic and
clinical factors that affected the response in multivariate
models. The degree of explanation of the variance in the
models was moderate, IADL: (R2 = 0.310, p < 0.001) and
PSMS: (R2 = 0.335, p < 0.001). The models and the signifi-
cant predictors are presented in Table 2.
Younger individuals showed a better response to treat-
ment after 6 months regarding both instrumental and
basic ADL abilities. In addition, there was a significant
interaction effect between cognitive and functional abil-
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As an example, a subject with an IADL score of 12
and an MMSE score of 15 at baseline showed an addi-
tional 3.6 points of IADL deterioration after 6 months,
on average, compared with an individual with an IADL
score of 20 and an MMSE score of 25. The variable anti-
depressant medications exhibited a trend towards signi-
ficance in the IADL model (p = 0.058), indicating that
depression may inhibit the response to ChEI therapy.
Patients taking a higher number of medications at base-
line exhibited a more negative treatment response, based
on the PSMS score. In contrast, individuals treated with
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Figure 2 Interaction effects between basic ADL and cognitive outcomes. Six-month mean Physical Self-Maintenance Scale (PSMS) outcomes
with 95% confidence intervals predicted by the general linear models for patients with PSMS scores of: a. 8 and b. 10 at the start of ChEI
treatment. A significant interaction effect was observed between cognitive and functional abilities at baseline (p = 0.008), i.e., a higher level of
cognition and more impaired ADL ability implied increased response to ChEI therapy. In the figures, Mini-Mental State Examination (MMSE) scores
(15, 20 and 25 were chosen as arbitrary examples) were used to illustrate the interaction. The calculated outcomes were based on a 75-year-old
patient who did not receive NSAID/acetylsalicylic acid treatment and had three medications at baseline.
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of MMSE score as an independent variable in the multi-
variate models yielded similar results; therefore, these
results are not presented here.
The variables gender, carrier of the APOE ε4 allele,
solitary living, medication use (antihypertensive/cardiac
therapy, anti-diabetic drugs, lipid-lowering agents, estro-
gens, anti-psychotics or anxiolytics/sedatives/hypnotics),
age at onset (or duration of AD), years of education, type
of ChEI agent, drug dose and the interaction effects of
gender × ADL ability, age × ADL ability or type of ChEI ×
dose were not significant when included in the models.
Better ADL ability at baseline and a more rapid func-
tional decline after 6 months of ChEI therapy showed a
weak linear relationship (n = 784; IADL: r = 0.198,
p < 0.001; and PSMS: r = 0.140, p < 0.001). The initial
change in MMSE score during the first 6 months of treat-
ment exhibited a weak positive linear association with
change in IADL (n = 778, r = 0.194, p < 0.001) and PSMS
(n = 778, r = 0.130, p < 0.001) score, respectively.
Functional outcome after 3 years of ChEI treatment
After 3 years, 339 patients (43%) remained in the study.
No difference in completion rate was found between the
improved/unchanged vs deteriorated IADL responder
groups, but 47% of the individuals in the improved/un-
changed PSMS group completed the study compared with
32% in the deteriorated group (χ2(1) = 14.91; p < 0.001).
The difference in IADL score between 6 months and the
baseline score exhibited a moderate linear relationship
with the 3-year IADL difference (n = 309, r = 0.449,
p < 0.001), whereas the 6-month difference in PSMS
score showed a weak correlation with the 3-year PSMSdifference (n = 309, r = 0.214, p < 0.001). The patients in
the improved/unchanged IADL responder group after 6
months of ChEI therapy showed a significantly higher
IADL status after 3 years than did the deteriorated group
(mean ± SD, 20.0 ± 6.9 vs 22.5 ± 5.9 points; t(307) = 3.38;
p = 0.001). The improved/unchanged PSMS responder
group exhibited, on average, better 3-year basic ADL abi-
lity compared with the deteriorated group (9.5 ± 3.7 vs
11.8 ± 4.2 PSMS points; t(307) = 4.30; p < 0.001). The
improved/unchanged responder groups received a greater
percentage of the maximum recommended ChEI dose
than did the deteriorated groups during the 3-year study:
IADL: (68 ± 18 vs 65 ± 18 %; t(782) = −2.11; p = 0.035);
PSMS: (67 ± 18 vs 63 ± 19 %; t(782) = −2.61; p = 0.009).
Discussion
In this study, which was performed in a clinical practice
setting, we found that 49% and 74% of the AD patients
showed improvement/no change in IADL and in basic
ADL ability, respectively, after 6 months of ChEI treat-
ment. The improved/unchanged groups showed a sig-
nificantly better cognitive status at baseline. Regarding
improved/unchanged basic ADL, patients in this group
were younger and used fewer anti-depressants. More-
over, there was a significant interaction effect between
cognitive and functional abilities at baseline, i.e., better
preserved cognition and more impaired ADL ability im-
plied increased functional response to ChEI therapy. The
outcome was similar regardless of the use of MMSE or
ADAS-cog scores, which gives credibility to the results.
Younger individuals also exhibited a better 6-month
response to treatment. Patients taking a higher number
of medications at baseline exhibited a more negative
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acetylsalicylic acids showed a better response to ChEI. No
difference in ADL response was detected among ChEI
agents after adjusting for background variables.
ADL performance in AD shows a moderate linear as-
sociation with cognitive ability (r = 0.4–0.7) among both
untreated [32,33] and treated patients [34]. Therefore,
ADL scales are a complement and an essential part of
the assessment of the patient and might produce a more
complete understanding of the effect of AD therapies
[35]. The pharmacological therapeutic drugs available
currently, ChEIs, have yielded improvements, on aver-
age, in cognition in several 6-month randomised clinical
trials [36] and have shown positive cognitive effects in
longer-term naturalistic studies [26,37]. Conversely, ChEIs
tend to provide a slowing or delay of functional decline,
on group level, rather than an improvement over the first
6 months of treatment.
Patient characteristics that might affect the short-term
effect of ChEI treatment on ADL ability have not been
investigated in previous naturalistic AD studies. Our
group has recently published a paper on the socio-
demographic and clinical predictors that influence the
long-term functional outcome in ChEI-treated AD pa-
tients [10]. The 6-month response of ADL demonstrated
a weak-to-moderate linear relationship with functional
status after 3 years. Thus, the factors that might predict
the short-term ChEI response are not necessarily equal
to those that predict the longitudinal outcome. Higher
cognitive ability and younger age at baseline were both
independent predictors of better functional short-term
response to ChEI and long-term treatment effect. In the
present study, fewer medications at baseline or NSAID/
acetylsalicylic acid therapy predicted a more positive 6-
month basic ADL response to ChEI; these variables were
not addressed in our previous analyses of the 3-year
functional outcome. A higher dose of ChEI and living
with a family member were independent predictors of
better long-term IADL ability, but not of the short-term
response of IADL. The difference in the results of ChEI
dose might reflect the regular dose titration that always
takes place during the first weeks of treatment, which in-
evitably led to a lower mean dose of ChEI in the first 6
months. The current study shows that the patients in
both the improved/unchanged IADL and PSMS groups
after 6 months of ChEI therapy received a higher mean
dose of ChEI during the following years than did the
deteriorated groups and demonstrated better ADL status
at the end of the 3-year study. This might imply that the
individuals who responded and could tolerate higher
doses exhibited a more positive long-term functional
outcome. The faster IADL deterioration among solitary
living AD patients observed over a longer period of time
might reflect symptoms of depression, apathy and socialisolation [10]. The heterogeneity in functional response
to the initiation of ChEI therapy highlights the import-
ance of identifying specific subgroups of patients with
differential response to treatment. Rapidly progressing
patients require more resources from caregivers and so-
cial services [33].
A significant interaction between cognitive and func-
tional abilities at baseline regarding response to ChEI
treatment was identified in this study of mild-to-mode-
rate AD patients. Higher cognitive status and lower ADL
ability implied increased functional response to ChEI
therapy. Therefore, the effects of these domains should
not be interpreted separately. The present study only de-
monstrated a weak linear association between cognitive
and ADL response after 6 months; thus, the predictors
of response might differ between the domains. Previous
studies from our group [19] and from others [9,38], but
not all [22], observed that more cognitive impaired indi-
viduals exhibited a better 6-month cognitive response to
ChEI treatment, emphasizing the importance of not ex-
cluding this group from treatment opportunities.
Prior work has reported that cognitive deficits are a risk
factor for functional impairment among the elderly, even
after adjusting for socio-demographic and medical cha-
racteristics [39]. Bullock & Lane [40] reported improved
executive function and attention among patients with de-
mentia that responded to rivastigmine therapy. Moreover,
a relationship between executive dysfunction and dimin-
ished instrumental and basic ADL was observed [41]. Bet-
ter function in the above-mentioned cognitive abilities
might lead to a more positive response in ADL. A recent
6-month study of donepezil [22] showed that the mild AD
group (MMSE ≥ 21) exhibited significantly less decline in
ADL compared with the moderate group (MMSE < 21),
which agrees with our findings. In contrast, subsequent
analyses of donepezil [42] and rivastigmine [38] clinical
trials showed that the functional benefit of the drug com-
pared with the placebo was greatest in the moderate and
moderately severe AD groups. However, those studies did
not address the cognitive-functional interaction effect or
the multivariate impact of other background variables.
In the present paper, significantly fewer AD patients in
the improved/unchanged basic ADL group used anti-
depressants. This type of medication also tended to
affect the IADL response negatively in the multivariate
model (p = 0.058). Depression is considered as a charac-
teristic of fronto-subcortical pathology. Patients with a
significant burden of this pathology, concomitant with a
heavier load of AD pathology, may show a more aggres-
sive course of disease [40]. Furthermore, Atchison et al.
[43] observed that the rapidly declining AD patients, as
measured using basic ADL ability, had higher levels of
self-reported depressive symptoms at the initial eva-
luation. Although significance was borderline in the
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if treated pharmaceutically, might be related to faster
functional deterioration and less response to ChEI.
This study also demonstrated that individuals using
NSAIDs/acetylsalicylic acid responded better to ChEI
regarding basic, but not instrumental, ADL. A recent stu-
dy from our group suggested that this category of medica-
tion was also a predictor of a more positive cognitive
response to ChEI [19]. In contrast, a recent placebo-
controlled randomised trial of NSAID treatment has failed
to show any positive effects on cognition or function in
AD [44]. One explanation might be the shorter treatment
period in that clinical trial compared with the longer per-
spective of the naturalistic SATS patients. Furthermore,
NSAID/acetylsalicylic acid therapy implies a symptomatic
effect on pain, which in cognitively impaired elderly indi-
viduals may be more difficult to assess and recognize [45].
Under-treated pain can have adverse functional conse-
quences and, therefore, analgesics might positively influ-
ence the response of ADL.
The predictors younger age or fewer concomitant
medications (basic ADL only) independently demons-
trated a better functional response to ChEI therapy in
the present study; these individuals exhibited less ADL
impairment at the start of treatment. In older patients,
the functional response might be more influenced by
physical disability, impaired senses or medical conditions
not related to AD [46]. A linear association between
cognitive status and number of medications at baseline
was not observed in the present study. This agrees with
another multivariate study from our group, in which
concomitant medications were not a significant pre-
dictor of response regarding cognition [19]. In that
study, older patients exhibited better 6-month cognitive
response and long-term outcome. In contrast, older age
predicted more rapid longitudinal decline in both instru-
mental and basic ADL abilities [10]. A more pronounced
decline in daily function because of the natural aging
process in older individuals, compared with cognition,
might negatively affect the functional response observed
in the present paper.
The advantages of the SATS are the 6-month, pro-
spective, well-documented cognitive and functional eva-
luations after ChEI exposure in a large cohort of AD
patients. The inclusion of everyday patients with co-
morbidities and concomitant medications provides an
essential supplement to data generated in clinical trials.
The SATS, like other long-term naturalistic studies, is
limited because it is not placebo controlled (because of
ethical aspects) or randomised with respect to drug use.
The treating physician, specialized in dementia disorders,
decided the type of ChEI and the dose according to the
standard routine in clinical practice. To minimize possible
differences between the treatment groups, multivariatemodels that took into account demographic and baseline
clinical factors were used. Other medical conditions, such
as concomitant somatic diseases that may influence ADL
ability, were not evaluated in the SATS programme.
Therefore, the number of medications was used as an in-
dicator of co-morbidity. The functional response to ChEI
therapy might be complex among elderly AD patients in
clinical practice. The inclusion of additional predictors,
not assessed in the SATS, might influence the multivariate
models and affect the individual’s outcome in ADL. How-
ever, the shorter follow-up time analysed in the present
paper might imply less influence of factors associated
with, e.g., multimorbidity in comparison with longer-term
studies.
In the future, additional well-structured naturalistic
studies will be required to advance our understanding of
the significant predictors that independently modify
responses to AD therapy [47]. The results presented
here need to be confirmed by other studies using data
from other naturalistic cohorts. The socio-demographic
and clinical composition of the study population may be
one of the explanations for the varying responses to
ChEI observed in different AD clinical trials. A predictor
such as age might provide different responses in diffe-
rent domains, and certain medications/co-morbidities,
e.g., NSAIDs/acetylsalicylic acid and depression, might
also alter the response [19]. The knowledge obtained
from ChEI response in specific subgroups can increase
the quality of care by aiding the clinicians and social ser-
vices in decision making and planning for the future.
Furthermore, it may provide more accurate information
regarding treatment expectations in counselling to pa-
tients and families.
Conclusions
In conclusion, critical characteristics that may influence
the functional response to ChEI were identified in this
naturalistic AD study. A significant interaction effect sho-
wed that higher cognitive and lower ADL abilities at ba-
seline implied increased functional response to ChEI
therapy. Younger age, NSAID/acetylsalicylic acid therapy
and fewer concomitant medications also predicted a posi-
tive response. Some of these significant predictors differed
from those observed earlier as affecting the cognitive re-
sponse to ChEI, e.g., more cognitive impairment and older
age predicted worse functional but better cognitive re-
sponse. The patients in both IADL and PSMS improved/
unchanged responder groups received a higher mean
ChEI dose during the following years, indicating that they
could tolerate higher doses. These individuals also exhib-
ited better functional status, on average, at the end of the
3-year study. Thus, early identification of patients with a
better probability of response is important to improve the
effectiveness of ChEI therapy and possibly reduce the need
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http://www.biomedcentral.com/1471-2377/12/134and costs of care. Knowledge of differences in response is
necessary to increase the understanding of ChEIs and to
compile informed treatment recommendations for clinical
practice. Functional ability is a key domain in maintaining
independent living; therefore, functional assessments and
response to therapy should be regarded as being at least
as important as cognitive outcomes.
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